Clinical Report: Efficacy of Ofatumumab in Refractory Anti-NMDAR Encephalitis
Overview
This report details three cases of refractory anti-NMDAR encephalitis patients who showed significant improvement in neuropsychiatric symptoms after treatment with ofatumumab. The findings suggest that ofatumumab is a rapid, safe, and effective therapeutic option for patients unresponsive to conventional treatments.
Background
Anti-NMDAR encephalitis is a prevalent autoimmune encephalitis characterized by severe neuropsychiatric symptoms due to autoantibodies targeting the NMDAR. Standard immunotherapy often fails in some patients, necessitating alternative treatments. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, presents a promising option for refractory cases, with limited real-world data available.
Data Highlights
Patient
Improvement in Symptoms
CD20+ B Cell Levels
Patient 1
Significant
Declined to low levels
Patient 2
Significant
Declined to low levels
Patient 3
Significant
Declined to low levels
Key Findings
All three patients exhibited significant improvement in psychiatric symptoms and cognitive function post-treatment.
CD20+ B cell levels rapidly declined to extremely low levels following ofatumumab administration.
Only one patient experienced mild adverse effects, including bone pain and low-grade fever.
Follow-up imaging and neurological assessments confirmed effective disease control.
Ofatumumab was well-tolerated, with no severe adverse events reported.
Clinical Implications
Ofatumumab may serve as a viable second-line treatment for patients with refractory anti-NMDAR encephalitis, particularly those unresponsive to first-line therapies. Clinicians should consider its use in similar cases, given its rapid efficacy and favorable safety profile.
Conclusion
The findings from this case series support the use of ofatumumab as an effective treatment for refractory anti-NMDAR encephalitis, highlighting the need for further studies to validate these results in larger populations.
